Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.5.1.52 (
PNGase F
)
1,527
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Surfactant protein D
(
SP-D
) is a member of the collectin family that has an important role in maintaining pulmonary homeostasis. In this study, we demonstrated that
SP-D
inhibited the proliferation, migration and invasion of A549 human lung adenocarcinoma cells. We found that
SP-D
suppressed epidermal growth factor (EGF) signaling in A549 cells, H441 human lung adenocarcinoma cells and human EGF receptor (EGFR) stable expression CHO-K1 cells. A binding study using (125)I-EGF demonstrated that
SP-D
downregulated the binding of EGF to EGFR. A ligand blot indicated that
SP-D
bound to EGFR, and a lectin blot suggested that EGFR in A549 cells had both high-mannose type and complex type N-glycans. We purified the recombinant extracellular domain of EGFR (soluble EGFR=soluble EGFR (sEGFR)), and demonstrated that
SP-D
directly bound to sEGFR in a Ca(2+)-dependent manner. The binding of
SP-D
to sEGFR was suppressed by EDTA, mannose or N-
glycopeptidase
F treatment. Mass spectrometric analysis indicated that N-glycans in domain III of EGFR were of a high-mannose type. These data suggest that
SP-D
reduces EGF binding to EGFR through the interaction between the carbohydrate recognition domain of
SP-D
and N-glycans of EGFR, and downregulates EGF signaling. Our finding suggests the novel type of regulation system of EGF signaling involving lectin-to-carbohydrate interaction and downregulation of ligand binding.
...
PMID:Surfactant protein D suppresses lung cancer progression by downregulation of epidermal growth factor signaling. 2625 Aug 51